FHL-801

FHL-801 is a **preclinical monoclonal antibody program** being developed by Forest Hills Business Association for long-term development in neurodegenerative disease. Publicly available pipeline information does not disclose a specific molecular target, binding epitope, route of administration, dosage form, or disease indication for this candidate. Company-level preclinical platform descriptions indicate general goals of neuronal protection, lysosomal biogenesis-mediated clearance of pathogenic molecules, and attenuation of brain inflammation, but these effects have not been specifically attributed to a defined target or disease setting for FHL-801.

Other names

FHL-801-Forest Hills Business Association-monoclonal antibodyFHL801-Forest Hills Business Association-monoclonal antibodyFHL 801-Forest Hills Business Association-monoclonal antibody